Literature DB >> 31145897

Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease?

S Elzinga1, B J Murdock1, K Guo2, J M Hayes1, M A Tabbey1, J Hur2, E L Feldman3.   

Abstract

Neuropathy is a common, morbid complication of the metabolic syndrome, prediabetes, and diabetes. Recent studies have indicated a potential role for the immune system in the development of neuropathy. In particular, toll-like receptors (TLR) 2 and 4 have been linked to metabolic dysfunction, and blocking TLR4 is proposed as a treatment for neuropathic pain. In the current study, we investigated the role of the immune system, particularly TLRs 2 and 4, in the pathogenesis and progression of neuropathy. Sural or sciatic nerve gene expression arrays from humans and murine neuropathy models of prediabetes and diabetes were first analyzed to identify differentially expressed TLR2- and TLR4-associated genes within the KEGG (Kyoto Encyclopedia of Genes and Genomes) database. We observed that genes associated with TLRs 2 and 4, particularly lipopolysaccharide binding protein (LPB) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB), were dysregulated across species and across multiple murine models of prediabetic and diabetic neuropathy. To further understand the role of these pathways in vivo, TLR 2 and 4 global knockout mice placed on a 60% high fat diet (HFD-TLR2/4-/-) were compared with wild type (WT) mice on a high fat diet (HFD-WT) and WT controls on a standard diet (CON). Mice then underwent metabolic, neuropathic, and immunological phenotyping at two time points to assess the impact of TLR signaling on neuropathy and immunity during metabolic dysfunction over time. We found that HFD-TLR2/4-/- and HFD-WT mice weighed more than CON mice but did not have increased fasting blood glucose levels. Despite normal blood glucose levels, HFD-TLR2/4-/- mice eventually developed neuropathy at the later time point (28 wks of age) but were somewhat protected from neuropathy at the early time point (16 wks of age) as measured by shorter hind paw withdraw latencies. This is in contrast to HFD-WT mice which developed neuropathy within 11 wks of being placed on a high fat diet and were neuropathic by all measures at both the early and late time points. Finally, we immunophenotyped all three mouse groups at the later time point and found differences in the number of peripheral blood Ly6C-myeloid cells as well as F4/80+ expression. These results indicate that TLR signaling influences early development of neuropathy in sensory neurons, potentially via immune modulation and recruitment.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  High fat diet; Peripheral neuropathy; Toll-like receptor 2 and 4

Year:  2019        PMID: 31145897      PMCID: PMC6708507          DOI: 10.1016/j.expneurol.2019.112967

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  14 in total

Review 1.  The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy.

Authors:  Seyed Hossein Aghamiri; Khalil Komlakh; Mehran Ghaffari
Journal:  Inflammopharmacology       Date:  2022-01-12       Impact factor: 4.473

Review 2.  Obesity-Associated Neuropathy: Recent Preclinical Studies and Proposed Mechanisms.

Authors:  Raiza Bonomo; Sarah Kramer; Virginie M Aubert
Journal:  Antioxid Redox Signal       Date:  2022-05-23       Impact factor: 7.468

3.  Systems Biology to Address Unmet Medical Needs in Neurological Disorders.

Authors:  Masha G Savelieff; Mohamed H Noureldein; Eva L Feldman
Journal:  Methods Mol Biol       Date:  2022

4.  Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes.

Authors:  Baoyan Fan; Chao Li; Alexandra Szalad; Lei Wang; Wanlong Pan; Ruilan Zhang; Michael Chopp; Zheng Gang Zhang; Xian Shuang Liu
Journal:  Diabetologia       Date:  2019-11-19       Impact factor: 10.122

Review 5.  Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy.

Authors:  Amro M Stino; Amy E Rumora; Bhumsoo Kim; Eva L Feldman
Journal:  J Peripher Nerv Syst       Date:  2020-06       Impact factor: 3.494

Review 6.  Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?

Authors:  Mark Yorek
Journal:  Curr Diabetes Rev       Date:  2022

7.  Immune-mediated vincristine-induced neuropathy: Unlocking therapies.

Authors:  Masha G Savelieff; Eva L Feldman
Journal:  J Exp Med       Date:  2021-05-03       Impact factor: 14.307

Review 8.  Recent Advances in Biomarkers and Regenerative Medicine for Diabetic Neuropathy.

Authors:  Yoshikai Fujita; Tatsufumi Murakami; Akihiro Nakamura
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

9.  Lipopolysaccharide-binding protein is a distinctive biomarker of abnormal pain threshold in the general Japanese population.

Authors:  Kazuhiro Kudoh; Hiroki Mizukami; Chieko Itabashi; Nobuo Fuke; Sho Osonoi; Yuki Takeuchi; Kanichiro Wada; Akiko Igawa; Saori Ogasawara; Yasuyuki Ishibashi; Kenichi Hakamada; Soroku Yagihashi; Shigeyuki Nakaji
Journal:  BMJ Open Diabetes Res Care       Date:  2020-10

10.  Genome-wide profiling of DNA methylation and gene expression identifies candidate genes for human diabetic neuropathy.

Authors:  Kai Guo; Stephanie A Eid; Sarah E Elzinga; Crystal Pacut; Eva L Feldman; Junguk Hur
Journal:  Clin Epigenetics       Date:  2020-08-12       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.